Identification of Human Blood on the Basis of the Fibrin Plate Method

The method of identifying human blood is studied from the standpoint of the fibrinolytic enzyme system by means of the &#34;fibrin plate method&#34; and the following results are obtained: 1) &#34;Fibrin plate method&#34; is, in the point of its sensitivity and speciesspecificity, one of the most excellent methods for the identification of human blood. 2) A small amount of the blood stains left standing as long as for 5 to 30 years can serve in the determination of the human blood. 3) Putrefied fluid blood does not demonstrate fibrinolysis. 4) Blood stains absorbed in various objects can also he identified whether they are of the human origin or not. 5) The pieces of cloth stained with human blood give positive fibrinolysis even after four washings with soap or after heating at 100°C for one hour. On the other hand, positive results are obtained with the pieces of cloths after three washings by benzidine test and with the physiological saline-extracted solution obtained after two washings of pieces of cloth, by precipitation test. 6) Proactivator has been found to contain globulin fraction in human serum protein. 7) The blood type can be determined with the same materials previously examined by the &#34;fibrin plate method&#34;.</p

Global NLO Analysis of Nuclear Parton Distribution Functions

Nuclear parton distribution functions (NPDFs) are determined by a global analysis of experimental measurements on structure-function ratios F_2^A/F_2^{A'} and Drell-Yan cross section ratios \sigma_{DY}^A/\sigma_{DY}^{A'}, and their uncertainties are estimated by the Hessian method. The NPDFs are obtained in both leading order (LO) and next-to-leading order (NLO) of \alpha_s. As a result, valence-quark distributions are relatively well determined, whereas antiquark distributions at x>0.2 and gluon distributions in the whole x region have large uncertainties. The NLO uncertainties are slightly smaller than the LO ones; however, such a NLO improvement is not as significant as the nucleonic case.Comment: 3 pages, LaTeX, 4 eps files, to be published in the AIP proceedings of the 9th International Workshop on Neutrino Factories, Superbeams and Betabeams (NuFact07), Okayama, Japan, August 6 - 11, 2007. A code for calculating our nuclear parton distribution functions and their uncertainties can be obtained from http://research.kek.jp/people/kumanos/nuclp.htm

Post mortem activation of human blood fibrinolytic enzyme in sudden and natural deaths

With the purpose to elucidate the cause and difference of blood fluidity in sudden death and natural one, we have observed the fibrinolysis of the blood in medico-legal and pathological autopsies by means of Fibrin Plate Method, a routine method devised in our laboratory. As the result it has been found that in the blood serum of sudden death and in some of natural deaths from tumors, leukemias, etc., the decrease in fibrinolytic activity is equivalent to the amount of proactivator that combined with the SK-like substance liberated into blood. On the other hand, in the blood of most of natural deaths, and in that bled from vessels and stored in body cavities, no natural fibrinolysis is observable and the same fibrinolytic activity with SK as normal one is demonstrated. Thus it is concluded that the cause of blood fluidity in sudden death is due to the fibrinolysis.</p

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant drugs have been used to prevent and treat thrombosis. However, they are associated with risk of hemorrhage. Therefore, prior to their clinical use, it is important to assess the risk of bleeding and thrombosis. In case of older anticoagulant drugs like heparin and warfarin, dose adjustment is required owing to narrow therapeutic ranges. The established monitoring methods for heparin and warfarin are activated partial thromboplastin time (APTT)/anti-Xa assay and prothrombin time – international normalized ratio (PT-INR), respectively. Since 2008, new generation anticoagulant drugs, called direct oral anticoagulants (DOACs), have been widely prescribed to prevent and treat several thromboembolic diseases. Although the use of DOACs without routine monitoring and frequent dose adjustment has been shown to be safe and effective, there may be clinical circumstances in specific patients when measurement of the anticoagulant effects of DOACs is required. Recently, anticoagulation therapy has received attention when treating patients with coronavirus disease 2019 (COVID-19). In this review, we discuss the mechanisms of anticoagulant drugs—heparin, warfarin, and DOACs and describe the methods used for the measurement of their effects. In addition, we discuss the latest findings on thrombosis mechanism in patients with COVID-19 with respect to biological chemistry

Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors

Background Supplementation with antithrombin (AT) concentrates is now common in the treatment of congenital and acquired AT deficiency. However, there is no established consensus on the target and timing of supplementation. We aimed to elucidate the effects of AT deficiency on the balance between coagulation activation and inhibition using a thrombin generation assay as in vitro global assay. Methods Samples were prepared by admixing commercially acquired AT-deficient plasma with < 1% AT activity with pooled normal plasma. The AT activity in each sample was adjusted to 100, 90, 70, 50, 40, 30, 10, 5, and < 1%. A thrombin generation assay was performed in each sample. AT concentrate-spiked samples were also prepared by adjusting the AT activities in four types of the concentrates: one recombinant and three plasma-derived AT concentrates. The final targeted AT activities in the samples were adjusted to 100, 50, 30, and 5% by spiking each concentrate into the AT-deficient plasma. We also prepared samples with five levels of prothrombin time (PT) % in coagulation factors with the AT activity fixed at 30% by dilution by mixing AT-deficient plasma and normal plasma with Owren's veronal buffer to adjust the coagulation factor activities in several proportions. The theoretical target PT% values were 100, 66, 50, 40, and 30%. A thrombin generation assay was performed on all samples. Results The ability to generate thrombin depended on the AT activity, and the amount of thrombin generation was increased as AT was decreased. Additionally, the amount of thrombin generation was changed significantly when AT activity was <= 50%, indicating that AT suppressed thrombin generation. In particular, thrombin generation was remarkable when AT activity was < 30%, and it can be assumed that the prognosis is poor due to organ failure from thrombotic tendency. Conclusions The results presented in this basic research were found to be consistent with the clinical findings to date. The mechanism by which 30-50% of AT activity is set as the clinical boundary was elucidated by the thrombin generation assay